Genome editing enables the targeted modification of a cell’s DNA, making it a powerful tool for fundamental biological research, early stage drug discovery, and for the development of novel cellular therapeutics. Due to its flexibility and ease of use, CRISPR has rapidly become one of the most important tools in the genome editing toolkit.
Researchers are currently exploring the use of different cargo types (such as plasmid, mRNA and protein) for delivering the Cas9 nuclease in combination with the target-specific guide RNA (gRNA) into a cell. The challenge is finding a cargo solution that provides highly efficient genome editing while minimizing unwanted off-target effects. Regardless of the cargo type selected, the molecules need to be successfully delivered into the cell - which can be difficult to achieve with some cell types, including human embryonic/induced pluripotent stem cells and primary T cells.
The non-viral Nucleofector™ Technology from Lonza is...
For CRISPR delivery, it has an established track record of success illustrated through over 50 peer-reviewed academic papers, published in high-ranking journals.
Download our whitepaper “Efficient CRISPR/Cas9 Delivery Using Nucleofector™ Technology: Comparison of Plasmid- and RNP-based Editing” to learn more. www.lonza.com/immunotherapy